POMDOCTOR LIMITED Shifts from ADR Program to Direct Listing of Shares on Nasdaq

POMDOCTOR LIMITED Ends ADR Program, Moves to Direct Listing on Nasdaq

On October 19, 2026, POMDOCTOR LIMITED, a pioneering company in digital healthcare, revealed significant changes in its stock listing strategy. The firm has opted to terminate its American Depositary Receipt (ADR) program and instead will directly list its Class A ordinary shares on Nasdaq under the ticker symbol 'POM'. This shift aims to enhance operational efficiency and simplify trading processes for shareholders.

The decision to end the ADR program was decisively approved by Pomdoctor's board of directors on September 3, 2026, and received a non-binding advisory endorsement from company shareholders during an extraordinary meeting held on September 30, 2026. The termination of the ADR program will officially take effect before the market opens on October 21, 2026, when the American Depositary Shares (ADSs) will be mandatorily cancelled and exchanged for Class A ordinary shares.

Share Consolidation and New Trading Details

Simultaneously with the end of the ADR program, Pomdoctor will implement a share consolidation initiative, wherein every ten ordinary shares of each class will be consolidated into one share. As a result, shareholders who previously held ten ADSs will receive three post-consolidation Class A ordinary shares. This consolidation aims to improve share liquidity and market presence.

The Class A ordinary shares are set to initiate trading on Nasdaq starting October 21, under a new CUSIP number: G7166T112. Additionally, the company has appointed TranShare Corporation as its transfer agent in the United States for managing the new Class A ordinary shares.

Company Background and Focus

Pomdoctor is primarily dedicated to advancing artificial intelligence (AI)-powered healthcare solutions and enhancing predictive healthcare capabilities. Their approach integrates physician resources, wearable technology, and real-time healthcare data to deliver personalized, data-driven services aimed at improving healthcare outcomes.

The firm emphasizes its commitment to transitioning healthcare methodologies from reactive to proactive frameworks, leveraging its established healthcare platform and extensive physician network. By investing in new technologies, Pomdoctor seeks not only to enhance patient care but also to create long-term value for all stakeholders involved, including patients, healthcare providers, and the broader healthcare ecosystem.

Forward-Looking Statements

This announcement includes forward-looking statements defined under relevant U.S. securities laws. These statements reflect current expectations, strategic plans, and potential outcomes regarding Pomdoctor's goals of transforming healthcare delivery through data-driven technologies and preventive healthcare strategies. While the company includes risk factors in its assessments, actual results may vary from those anticipated.

Investors should carefully consider the potential risks detailed in Pomdoctor's filings with the Securities and Exchange Commission (SEC), including those outlined in the company's Annual Report filed on May 14, 2026.

For investors seeking more information about Pomdoctor's plans and ongoing initiatives, the company invites inquiries through its Investor Relations department and its official corporate website. The transition marks a new chapter for Pomdoctor, setting the stage for enhanced market engagement and improved shareholder alignment in the digital healthcare sector.